Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NARecruitingINTERVENTIONAL
Enrollment
300
Participants
Timeline
Start Date
December 13, 2021
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Conditions
Breast Cancer
Interventions
DRUG
Tc99m sestamibi
Given by IV
Trial Locations (1)
77030
RECRUITING
M D Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT05042687 - Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer | Biotech Hunter | Biotech Hunter